Participants
From a total population of 233 HAE patients recruited from four academic
expert centers in Israel, 197 patients (84.5%) agreed to participate in
a preliminary survey, addressing their medical, ethnic, socio-economic
background, demographics, and health-related items. Out of these, 66
physican-diagnosed HAE patients consented and qualified to join the
study (Table II). Main inclusion criteria were: confirmed diagnosis of
HAE based on personal and family history of angioedema attacks;
antigenic C1-INH below normal range; and/or functional C1-INH
<50% and complement C4 below normal range (Type I). Patients
with normal antigenic C1-INH, low functional C1-INH and low C4 (Type II)
were also included. Angioedema patients with normal C1-INH and normal C4
were excluded. Only Hebrew-speaking patients participated in the study.
The study was approved and supervised by the ethics committees of
Tel-Aviv University, Sheba Medical Center and Barzilai Medical center.
All patients signed an informed-consent form (ICF). Mean age of
participants was 32.4 years (SD ±16.4), Median age 30.0 years (age range
10-70(. 22.3% were children and adolescents and 59.1% were females
(Table II).